Claritev (CTEV, Financial) has announced strategic new appointments to its senior leadership team as part of its ongoing mission to enhance healthcare transparency through innovative technology and solutions. The company aims to bolster its growth and transformation efforts with these leadership additions.
Dr. Jigar Patel has been appointed as the Chief Medical Officer. In his new role, Patel will offer medical insights into the strategic development and innovations of Claritev's healthcare technology solutions. He brings over 18 years of experience from his previous role at Cerner/Oracle, where he collaborated with major national healthcare firms on healthcare information technology strategy.
Fernando Schwartz, Ph.D., has taken on the position of Chief Artificial Intelligence Officer. Leading the AI and Data Science Department under Chief Digital Officer Michael Kim, Schwartz is tasked with spearheading the company's AI strategy, along with developing new products and capabilities. His prior experience includes a role as Vice President of AI at ADP, where he advanced AI initiatives that aligned with business objectives.
These appointments are part of Claritev's broader strategy to leverage expert leadership in guiding the company's innovative solutions within the healthcare sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Claritev Corp (CTEV, Financial) is $13.67 with a high estimate of $21.00 and a low estimate of $10.00. The average target implies an downside of 32.69% from the current price of $20.31. More detailed estimate data can be found on the Claritev Corp (CTEV) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Claritev Corp's (CTEV, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Claritev Corp (CTEV, Financial) in one year is $48.49, suggesting a upside of 138.81% from the current price of $20.305. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Claritev Corp (CTEV) Summary page.
